Declaratory Relief Complaint for Patent Infringement under Patent based on Manufacture, Marketing and Sale of Arzerra

Declaratory Relief Complaint for Patent Infringement under Patent based on Manufacture, Marketing and Sale of Arzerra
Copenhagen, Denmark; March 25, 2010 - Genmab A/S (OMX: GEN) announced today that on March 23, 2010 Genentech, Inc. and Biogen Idec, Inc. filed a declaratory relief complaint at the US District Court, Southern District of California against Genmab's collaboration partner GlaxoSmithKline (GSK) for patent infringement under US patent No 7,682,612 based on GSK's manufacture, marketing and sale of ArzerraTM in the United States for the treatment of fludarabine and alemtuzumab refractory chronic lymphocytic leukemia (CLL).

US patent No 7,682,612 was issued to Genentech, Inc. and Biogen Idec, Inc. on March 23, 2010 and contains a claim to a method of treating CLL with anti-CD20 antibodies, wherein the method does not comprise treatment with radiolabeled anti-CD20 antibodies.

Genmab will in collaboration with GSK assess and analyze the claims under the initiated legal action and determine the appropriate action in response to the complaint.

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.